Beyond targeting malignant B cells
Mené sur 52 patients atteints d'un lymphome à cellules du manteau réfractaire ou récidivant, cet essai de phase I/II évalue un traitement combinant lénalidomide et rituximab
The anticipated overall survival for mantle-cell lymphoma (MCL) has significantly improved over the past 30 years; however, it is still only in the range of 4—5 years. 1 Patients with MCL commonly respond to initial treatment but a persistent pattern of relapse usually follows and chemoresistance commonly develops over time. A few highly selected patients have had favourable long-term disease-free survival after allogeneic stem-cell transplantation, but for most patients there is no curative treat ...
The Lancet Oncology , commentaire, 2011